Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07443306 | A Clinical Trial of Flonoltinib Maleate Tablets in the Treatment of JAK Inhibitor Refractory/Relapsed/Intolerant Patients With Medium to High Risk Myelofibrosis | PHASE2 | RECRUITING | 64 | — | — | Mar 18, 2026 | Mar 30, 2028 | May 13, 2026 | 2 | China |
| Arm | Type | Description |
|---|---|---|
| Flonoltinib maleate | EXPERIMENTAL | Allocate 50mg or 75mg flonoltinib maleate tablets once daily on an empty stomach based on platelet count levels during the screening period |
| Name | Type | Description |
|---|---|---|
| Flonoltinib Maleate | DRUG | Allocate flonoltinib maleate tablets 50mg or 75mg once daily on an empty stomach based on platelet count levels during the screening period |
Inclusion Criteria: 1. Age range of 18-80 years old (including threshold), gender not limited; 2. Patients diagnosed with primary myelofibrosis (PMF) according to WHO criteria (2016 edition) or patients diagnosed with post polycythemia vera myelofibrosis (PPV-MF) or post thrombocytopenia myelofibro...